TREA

97786669 - PELMOFY

Follow

Information

  • Trademark
  • 97786669
  • Serial Number
    97786669
  • Filing Date
    February 08, 2023
    a year ago
  • Transaction Date
    November 02, 2024
    2 months ago
  • Status Date
    August 06, 2024
    5 months ago
  • Published for Opposition Date
    June 11, 2024
    7 months ago
  • Location Date
    August 06, 2024
    5 months ago
  • Status Code
    688
  • Current Location
    INTENT TO USE SECTION
    Employee Name
    STIGLITZ, SUSAN
  • Attorney Docket Number
    124033-90601
    Attorney Name
    Keith Toms, Esq.
    Law Office Assigned Location Code
    L90
  • Owners
Information
Mark Drawing Code
4
Mark Identification
PELMOFY
Case File Statements
  • GS0051: Pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations for the treatment of blood diseases; pharmaceutical preparations for the treatment of diseases of the bone marrow; pharmaceutical preparations for the treatment of cancer, namely, BET protein inhibitors; pharmaceutical preparations for the treatment of myelofibrosis; pharmaceutical preparation for the treatment of myelodysplastic syndrome (MDS); pharmaceutical preparations for the treatment of myeloproliferative neoplasm; pharmaceutical preparations for suppressing tumors; pharmaceutical preparations for the treatment of thrombocythemia; pharmaceutical preparations for the treatment of diseases that involve dysregulation of epigenetic pathways; pharmaceutical preparations for epigenetic modulators as therapeutics; pharmaceutical preparations comprising small molecules for treating cancer, myelofibrosis, myelodysplasic syndrome (MDS), myeloproliferative neoplasm, trombocythemia, anemia, low-risk myelodysplasic syndrome (MDS), essential thrombocythemia (ET) and diseases that involve dysregulation of epigenetic pathways; small molecule pharmaceuticals for the treatment of diseases and conditions, namely cancer, myelofibrosis, myelodysplasic syndrome (MDS), myeloproliferative neoplasm, trombocythemia, anemia, low-risk myelodysplasic syndrome (MDS), essential thrombocythemia (ET) and diseases that involve dysregulation of epigenetic pathways; pharmaceuticals and pharmaceutical preparations for human use for the treatment and prevention of diseases and disorders, namely cancer, myelofibrosis, myelodysplasic syndrome (MDS), myeloproliferative neoplasm, trombocythemia, anemia, low-risk myelodysplasic syndrome (MDS), essential thrombocythemia (ET) and diseases that involve dysregulation of epigenetic pathways; antibodies sold as a component ingredient of pharmaceuticals for the treatment of cancer, myelofibrosis, myelodysplasic syndrome (MDS), myeloproliferative neoplasm, trombocythemia, anemia, low-risk myelodysplasic syndrome (MDS), essential thrombocythemia (ET) and diseases that involve dysregulation of epigenetic pathways; antibodies for use in the manufacture of active ingredients of pharmaceuticals and vaccines for the treatment of cancer, myelofibrosis, myelodysplasic syndrome (MDS), myeloproliferative neoplasm, trombocythemia, anemia, low-risk myelodysplasic syndrome (MDS), essential thrombocythemia (ET) and diseases that involve dysregulation of epigenetic pathways; diagnostic preparations for medical purposes; clinical medical reagents; biological preparations for medical purposes, namely for the treatment of cancer, myelofibrosis, myelodysplasic syndrome (MDS), myeloproliferative neoplasm, trombocythemia, anemia, low-risk myelodysplasic syndrome (MDS), essential thrombocythemia (ET) and diseases that involve dysregulation of epigenetic pathways; pharmaceutical and veterinary preparations and agents for the treatment of cancer, myelofibrosis, myelodysplasic syndrome (MDS), myeloproliferative neoplasm, trombocythemia, anemia, low-risk myelodysplasic syndrome (MDS), essential thrombocythemia (ET) and diseases that involve dysregulation of epigenetic pathways
Case File Event Statements
  • 2/11/2023 - a year ago
    1 - NEW APPLICATION ENTERED Type: NWAP
  • 2/17/2023 - a year ago
    2 - NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Type: NWOS
  • 11/6/2023 - a year ago
    3 - ASSIGNED TO EXAMINER Type: DOCK
  • 11/6/2023 - a year ago
    4 - NON-FINAL ACTION WRITTEN Type: CNRT
  • 11/6/2023 - a year ago
    5 - NON-FINAL ACTION E-MAILED Type: GNRT
  • 11/6/2023 - a year ago
    6 - NOTIFICATION OF NON-FINAL ACTION E-MAILED Type: GNRN
  • 1/31/2024 - 11 months ago
    7 - APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED Type: XELR
  • 1/31/2024 - 11 months ago
    8 - APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED Type: XELG
  • 4/5/2024 - 9 months ago
    9 - TEAS RESPONSE TO OFFICE ACTION RECEIVED Type: TROA
  • 4/5/2024 - 9 months ago
    10 - CORRESPONDENCE RECEIVED IN LAW OFFICE Type: CRFA
  • 4/5/2024 - 9 months ago
    11 - TEAS/EMAIL CORRESPONDENCE ENTERED Type: TEME
  • 4/29/2024 - 8 months ago
    12 - FINAL REFUSAL WRITTEN Type: CNFR
  • 4/29/2024 - 8 months ago
    13 - FINAL REFUSAL E-MAILED Type: GNFR
  • 4/29/2024 - 8 months ago
    14 - NOTIFICATION OF FINAL REFUSAL EMAILED Type: GNFN
  • 5/8/2024 - 8 months ago
    15 - EXAMINERS AMENDMENT -WRITTEN Type: CNEA
  • 5/8/2024 - 8 months ago
    16 - EXAMINERS AMENDMENT E-MAILED Type: GNEA
  • 5/8/2024 - 8 months ago
    17 - NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED Type: GNEN
  • 5/8/2024 - 8 months ago
    18 - EXAMINER'S AMENDMENT ENTERED Type: XAEC
  • 5/8/2024 - 8 months ago
    19 - APPROVED FOR PUB - PRINCIPAL REGISTER Type: CNSA
  • 8/6/2024 - 5 months ago
    23 - NOA E-MAILED - SOU REQUIRED FROM APPLICANT Type: NOAM
  • 5/22/2024 - 8 months ago
    20 - NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Type: NONP
  • 6/11/2024 - 7 months ago
    21 - PUBLISHED FOR OPPOSITION Type: PUBO
  • 6/11/2024 - 7 months ago
    22 - OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Type: NPUB